Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Wheatley, P."'
Autor:
Abhenil Mittal, Sara Moore, Vishal Navani, Di Maria Jiang, David J. Stewart, Geoffrey Liu, Paul Wheatley-Price
Publikováno v:
Current Oncology, Vol 31, Iss 7, Pp 3738-3751 (2024)
Evidence from phase three clinical trials helps shape clinical practice. However, a very small minority of patients with cancer participate in clinical trials and many trials are not completed on time due to slow accrual. Issues with restrictive elig
Externí odkaz:
https://doaj.org/article/a3bf38414b674551b748beeaf12974b8
Autor:
David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist
Publikováno v:
Current Oncology, Vol 31, Iss 5, Pp 2453-2480 (2024)
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can
Externí odkaz:
https://doaj.org/article/e2a0bda42f934ee6ba8bb491b5743aa9
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Andrew Baird, Abdullah Nasser, Peter Tanuseputro, Colleen Webber, Paul Wheatley-Price, Camille Munro
Publikováno v:
Current Oncology, Vol 31, Iss 2, Pp 1028-1034 (2024)
Malignant pleural mesothelioma is a rare, aggressive, and incurable cancer with a poor prognosis and high symptom burden. For these patients, little is known about the impact of palliative care consultation on outcomes such as mortality, hospital adm
Externí odkaz:
https://doaj.org/article/d3a08fb0ebe94afc82ab281437b5c61e
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8363-8374 (2023)
Background: Limited research exists regarding how healthcare stakeholders prioritize the importance of differing physician attributes in oncologists. Identifying these priorities can help ensure that Canadian cancer care continues to meet the needs o
Externí odkaz:
https://doaj.org/article/e9c92405480b4f4e966ea343f394d79c
Autor:
Nicola Fenwick, Rebekah Weston, Keith Wheatley, Jodie Hodgson, Lynley Marshall, Martin Elliott, Guy Makin, Antony Ng, Bernadette Brennan, Stephen Lowis, Jenny Adamski, John Paul Kilday, Rachel Cox, Mike Gattens, Andrew Moore, Toby Trahair, Milind Ronghe, Martin Campbell, Helen Campbell, Molly W. Williams, Maria Kirby, Natasha Van Eijkelenburg, Jennifer Keely, Ugo Scarpa, Victoria Stavrou, Livingstone Fultang, Sarah Booth, Paul Cheng, Carmela De Santo, Francis Mussai
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe survival for many children with relapsed/refractory cancers remains poor despite advances in therapies. Arginine metabolism plays a key role in the pathophysiology of a number of pediatric cancers. We report the first in child study of
Externí odkaz:
https://doaj.org/article/4902b15b11094343be86c12a848d2cb8
Autor:
Ashley Jackson, BSc, Nina Chang, MD, Deborah Akurang, BSc, Paul Wheatley-Price, MD, Sara Moore, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100601- (2023)
Background: Immunotherapy has vastly changed the treatment landscape for patients with advanced NSCLC. With high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥50%), options include programmed cell death protein 1 or PD-L1 in
Externí odkaz:
https://doaj.org/article/f7a96bab9a6546fb887ec2448c0e6dfb
Autor:
Parneet K. Cheema, Shantanu O. Banerji, Normand Blais, Quincy S.-C. Chu, Rosalyn A. Juergens, Natasha B. Leighl, Adrian Sacher, Brandon S. Sheffield, Stephanie Snow, Mark Vincent, Paul F. Wheatley-Price, Stephen Yip, Barbara L. Melosky
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6473-6496 (2023)
Activating mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS), in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic alterations in non-small cell lung canc
Externí odkaz:
https://doaj.org/article/ab0cb512b2d24cbeafaef622627ed0b6
Autor:
Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6559-6574 (2023)
Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inh
Externí odkaz:
https://doaj.org/article/7a0dcc0fa9644dafb2573f4dd241ebd7
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6006-6018 (2023)
Concurrent chemoradiotherapy (CRT) is the standard of care for limited-stage small cell lung cancer (LS-SCLC). Local therapy—surgery or stereotactic body radiotherapy (SBRT)—with adjuvant chemotherapy may be appropriate for very early (T1-T2, N0)
Externí odkaz:
https://doaj.org/article/c0469e0eb9824a2a93cc8d124bd7ffb7